Fluconazole plus cyclosporine:: A fungicidal combination effective against experimental endocarditis due to Candida albicans

被引:94
作者
Marchetti, O
Entenza, JM
Sanglard, D
Bille, J
Glauser, MP
Moreillon, P [1 ]
机构
[1] CHU Vaudois, Dept Internal Med, Div Infect Dis, CH-1011 Lausanne, Switzerland
[2] CHU Vaudois, Inst Microbiol, CH-1011 Lausanne, Switzerland
关键词
D O I
10.1128/AAC.44.11.2932-2938.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Recent observations demonstrated that fluconazole plus cyclosporine (Cy) synergistically killed Candida albicans in vitro. This combination was tested in rats with C, albicans experimental endocarditis, The MICs of fluconazole and Cy for the test organism were 0.25 and >10 mg/liter, respectively, Rats were treated for 5 days with either Cy, amphotericin B, fluconazole, or fluconazole-Cy, Although used at high doses, the peak concentrations of fluconazole in the serum of rats (up to 4.5 mg/liter) were compatible with high-dose fluconazole therapy in humans. On the other hand, Cy concentrations in serum (up to 4.5 mg/liter) were greater than recommended therapeutic levels. Untreated rats demonstrated massive pseudohyphal growth in both the vegetations and the kidneys. However, only the kidneys displayed concomitant polymorphonuclear infiltration. The therapeutic results reflected this dissociation. In the vegetations, only the fungicidal fluconazole-Cy combination significantly decreased fungal densities compared to all groups, including amphotericin B (P < 0.0001), In the kidneys, all regimens except the Cy regimen were effective, but fluconazole-Cy remained superior to amphotericin B and fluconazole alone in sterilizing the organs (P < 0.0001), While the mechanism responsible for the fluconazole-Cy interaction is hypothetical, this observation opens new perspectives for fungicidal combinations between azoles and other drugs.
引用
收藏
页码:2932 / 2938
页数:7
相关论文
共 45 条
[1]   SAFETY, PLASMA-CONCENTRATIONS, AND EFFICACY OF HIGH-DOSE FLUCONAZOLE IN INVASIVE MOLD INFECTIONS [J].
ANAISSIE, EJ ;
KONTOYIANNIS, DP ;
HULS, C ;
VARTIVARIAN, SE ;
KARL, C ;
PRINCE, RA ;
BOSSO, J ;
BODEY, GP .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (02) :599-602
[2]  
BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247
[3]  
Brammer K.W., 1990, REV INFECT DIS S3, V12, P318
[4]   CANDIDA-ALBICANS ENDOCARDITIS - ULTRASTRUCTURAL STUDIES OF VEGETATION FORMATION [J].
CALDERONE, RA ;
ROTONDO, MF ;
SANDE, MA .
INFECTION AND IMMUNITY, 1978, 20 (01) :279-289
[5]   Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits [J].
Chemlal, K ;
SaintJulien, L ;
Joly, V ;
Farinotti, R ;
Seta, N ;
Yeni, P ;
Carbon, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (01) :263-266
[6]  
COLLIER SJ, 1986, LANCET, V1, P216
[7]   Synergistic antifungal activities of bafilomycin A1, fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans [J].
Del Poeta, M ;
Cruz, MC ;
Cardenas, ME ;
Perfect, JR ;
Heitman, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :739-746
[8]  
DEPAUW BE, 1997, INT J INFECT DIS S1, V1, P32
[9]   Genetic separation of FK506 susceptibility and drug transport in the yeast Pdr5 ATP-binding cassette multidrug resistance transporter [J].
Egner, R ;
Rosenthal, FE ;
Kralli, A ;
Sanglard, D ;
Kuchler, K .
MOLECULAR BIOLOGY OF THE CELL, 1998, 9 (02) :523-543
[10]   AMPHOTERICIN-B SERUM CONCENTRATIONS DURING THERAPY [J].
FIELDS, BT ;
BATES, JH ;
ABERNATHY, RS .
APPLIED MICROBIOLOGY, 1970, 19 (06) :955-+